drugset

drugset / Trial / NCT04217798

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

NCT04217798 ↗

Phase 2 Unknown 36 enrolled Peking Union Medical College Hospital Zai Lab (Shanghai) Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of niraparib combined with oral etoposide in platinum resistant or platinum refractory recurrent ovarian cancer.

Timeline

Start: 2020-05-21
Primary completion: 2022-03-01
Completion: 2022-06-01

Publications

Zhou H, Liu Q, Zhang D, Li Q, Cao D, Cheng N, Wan X, Zhang Y, Feng F, Xiang Y, Yang J. Efficacy and safety of an oral combination therapy of niraparib and etoposide in platinum resistant/refractory ovarian cancer: a single arm, prospective, phase II study. Int J Gynecol Cancer. 2024 Nov 4;34(11):1761-1767. doi: 10.1136/ijgc-2024-005386.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etoposide	Small molecule	50 mg	Oral
Subject	Niraparib	Small molecule	100 mg	Oral
Subject	Niraparib	Small molecule	200 mg	Oral

Indications